Case Details
- Citation: [2021] SGHC 246
- Case Title: Yong Khong Yoong Mark and others v Ting Choon Meng and another
- Court: High Court of the Republic of Singapore (General Division)
- Coram: Tan Siong Thye J
- Decision Date: 29 October 2021 (Judgment reserved; delivered 29 October 2021)
- Case Number: Suit No 1140 of 2018 and Summonses Nos 1688, 1975, 1976 and 2330 of 2021
- Judgment Length: 105 pages; 47,022 words
- Plaintiffs/Applicants: Yong Khong Yoong Mark; Emily Hwang Mei Chen; Medivice Investment Limited
- Defendants/Respondents: Ting Choon Meng; Chua Ngak Hwee
- Counsel for Plaintiffs: Nair Suresh Sukumaran, Yeow Guan Wei Joel and Bhatt Chantik Jayesh (PK Wong & Nair LLC)
- Counsel for Defendants: Khan Nazim, Kuan Chu Ching and Kunal Haresh Mirpuri (UniLegal LLC)
- Legal Areas: Contract (Misrepresentation; Misrepresentation Act); Evidence (Admissibility of evidence; hearsay); Tort (fraud and deceit; inducement; negligent misrepresentation; conspiracy by unlawful means)
- Statutes Referenced: Misrepresentation Act (Cap 390, 1994 Rev Ed) (notably s 2(1))
- Key Issues (as pleaded): Fraudulent and negligent misrepresentation; inducement; damages under s 2 Misrepresentation Act; unlawful means conspiracy; admissibility of evidence including hearsay
- Parties’ Roles (high level): Plaintiffs were investors and an investment vehicle; defendants were founders/executives of Healthstats International and related persons
Summary
This High Court decision concerns a claim by investors who alleged that they were induced to part with substantial sums to HealthSTATS International Pte Ltd (“Healthstats International”) and to enter a subscription arrangement, on the basis of representations said to have been made by the defendants about the company’s viability and prospects. The plaintiffs’ case was framed in both contract and tort: they pleaded fraudulent misrepresentation, negligent misrepresentation, and misrepresentation inducing entry into the relevant transactions. As an alternative statutory route, they also sought damages under s 2(1) of the Misrepresentation Act (Cap 390, 1994 Rev Ed). In addition, they pleaded conspiracy by unlawful means.
The defendants denied the alleged misrepresentations and the conspiracy. The judgment (delivered by Tan Siong Thye J) addresses the evidential and legal requirements for establishing misrepresentation—particularly the mental element for fraud, the standard for negligence in misstatement, and the causation/inducement link between the representations and the plaintiffs’ decision to invest. It also considers the requirements for conspiracy by unlawful means, including what constitutes “unlawful means” and the necessary participation and intent. The court’s analysis is informed by the documentary record and witness testimony, and it engages with evidential admissibility issues, including hearsay.
What Were the Facts of This Case?
The plaintiffs comprised Mr Yong Khong Yoong Mark, his wife Ms Emily Hwang Mei Chen, and Ms Hwang’s Cayman-incorporated investment vehicle, Medivice Investment Limited (“Medivice”). Ms Hwang was the sole shareholder and director of Medivice. Mr Yong was a director and shareholder of Uncharted Holdings Limited and founder of the Uncharted Group Limited, and he held interests in other listed and private investment structures. The plaintiffs’ investment decisions therefore occurred in the context of sophisticated private investing, which later became relevant to how the court assessed credibility, reliance, and causation.
The defendants were Dr Ting Choon Meng and Mr Chua Ngak Hwee, who were closely connected to Healthstats International. Dr Ting was a general medical practitioner and the plaintiffs’ personal physician, and he knew them personally. Dr Ting and Mr Chua founded Healthstats International in 2000. Dr Ting served as CEO from the company’s founding until March 2016 and later again from April 2017 to October 2017. Mr Chua was chief technology officer and remained a founding director until May 2018. Both defendants were shareholders of Healthstats International. The company’s chief financial officer was Mr Marcus Chua. The court also heard evidence from several present and former employees, including finance, production, R&D, and regulatory affairs personnel.
Healthstats International manufactured medical research and clinical diagnostic instruments, with flagship products relating to blood pressure measurement. The BPro devices were wearable, watch-like systems measuring blood pressure non-invasively; the CasPro devices measured central aortic systolic blood pressure non-invasively using radial artery pulse waves. The first generation BPro (BPro G1) had obtained regulatory approvals from the US FDA, the EU CE, Singapore’s HSA, and China’s CFDA. The second generation BPro (BPro G2) added Bluetooth functionality and was targeted at medical professionals; however, as at the end of 2016 it had not yet received US FDA approval (which was later obtained in June 2018). The third generation BPro (BPro G3) was intended as consumer wearables for mass market distribution and was developed around 2015.
Central to the dispute were Healthstats International’s commercial arrangements with its China subsidiary, Healthstats China, and the plaintiffs’ subsequent investment. Healthstats China became a joint venture when Winsan (Shanghai) Medical Science and Technology Co Ltd acquired 51% of its shares in July 2015, leaving Healthstats International with 49%. Winsan had been awarded tenders for remote monitoring of blood pressure in three Chinese cities and wanted Healthstats International to supply BPro devices and CasPro devices. Accordingly, Healthstats China entered into two contracts with Healthstats International in 2015 (the “China Contracts”): a first purchase agreement for S$5m worth of BPro G2 devices and accessories, and a second purchase agreement for a much larger total value (S$52.785m) covering BPro G2, BPro G3, and CasPro devices and accessories. The court’s narrative then turned to how these commercial realities were presented to the plaintiffs and how the plaintiffs’ loans and subscription investment were said to have been induced by representations about Healthstats International’s viability and product pipeline.
What Were the Key Legal Issues?
The first cluster of issues concerned misrepresentation in contract and tort. The court had to determine whether the defendants made representations that were false, and if so, whether they were fraudulent (requiring proof of dishonesty or knowledge of falsity/recklessness as to truth), negligent (requiring a duty and breach in making a statement without reasonable care), or otherwise actionable. The plaintiffs also had to establish inducement: that the misrepresentations caused or materially contributed to their decision to make loans and to enter the subscription agreement.
A second cluster concerned the statutory claim under the Misrepresentation Act, particularly s 2(1). That provision can shift the burden of proof and/or affect the availability of damages where a misrepresentation is made and the representor cannot establish that they had reasonable grounds to believe the statement was true (or that they took reasonable care, depending on the statutory framing). The court therefore had to consider how the statutory regime interacts with common law misrepresentation principles and what evidential threshold the plaintiffs needed to meet.
Third, the plaintiffs pleaded conspiracy by unlawful means. The court had to consider whether the defendants agreed to participate in a course of conduct involving unlawful means, and whether the plaintiffs were injured as a result. This required analysis of what “unlawful means” means in the conspiracy context, and whether the alleged misrepresentations could qualify as unlawful means, as well as whether the necessary intention and participation were established on the evidence.
How Did the Court Analyse the Issues?
The court’s approach to misrepresentation began with the pleaded narrative: the plaintiffs said that the defendants painted a misleading picture of Healthstats International’s viability, including that it had many products worth investing in. The court then had to identify the specific representations alleged, determine whether they were made, and assess their truthfulness against the factual background of regulatory approvals, product development status, and the company’s actual commercial position. This is often the most difficult stage in misrepresentation litigation because it requires careful separation between broad statements of optimism (which may be non-actionable opinion or sales talk) and concrete factual assertions about viability, regulatory status, or the existence of credible business prospects.
On fraudulent misrepresentation, the court would have required proof that the defendants made the statements knowing they were false or without caring whether they were true or false, and that the statements were intended to induce the plaintiffs to enter the transactions. The judgment’s structure (as indicated by the case metadata and the pleaded causes of action) suggests the court examined both the defendants’ mental state and the surrounding circumstances, including the defendants’ roles in Healthstats International, their knowledge of regulatory progress (for example, the timing of FDA approval for BPro G2), and their access to internal information. Where parties occupy positions of trust or where one party is a founder/executive, the court typically scrutinises whether the representor had actual knowledge of the true position.
For negligent misrepresentation, the analysis would have turned to whether the defendants owed a duty of care in making the statements, whether they breached that duty by failing to exercise reasonable care, and whether the plaintiffs reasonably relied on the statements. The court would also have considered whether the plaintiffs’ sophistication and investment experience affected reliance and causation. In misrepresentation cases, even where a statement is found to be inaccurate, the claimant must still show that the misstatement induced the transaction and that the loss claimed is linked to that inducement. The court therefore would have analysed the timeline: the loans made from January to July 2016 and the subscription agreement entered in August 2016, and how the alleged representations were connected to those decisions.
Regarding the Misrepresentation Act claim, the court would have considered the statutory pathway for damages where misrepresentation is established and where the representor’s defences under the Act are not made out. Section 2(1) is significant because it can allow damages in circumstances where the common law measure or proof requirements might otherwise be more demanding. The court’s reasoning likely addressed whether the plaintiffs’ pleaded misrepresentation fell within the statutory scope, and whether the defendants could show that they had reasonable grounds to believe the truth of the representations (or that they took reasonable care, depending on the statutory framing and how the claim was advanced). The evidential record—documents, communications, and witness testimony—would have been central to whether the defendants met their statutory burden.
On conspiracy by unlawful means, the court would have applied the established elements of the tort: an agreement between two or more parties to do an act, the use of unlawful means in furtherance of that agreement, and intention to injure (or at least the necessary mental element consistent with the pleaded case). The court would have examined whether the alleged misrepresentations constituted “unlawful means” and whether the defendants’ conduct amounted to more than independent wrongdoing. Conspiracy claims are particularly sensitive to proof because they require showing a common design or agreement, not merely parallel conduct. The judgment’s inclusion of evidence admissibility issues, including hearsay, indicates that the court had to decide what material could be relied upon to establish the conspiracy and the content of any alleged communications.
What Was the Outcome?
Based on the court’s ultimate disposition (not fully reproduced in the truncated extract provided), the High Court would have determined whether the plaintiffs proved misrepresentation—fraudulent, negligent, and/or inducement—and whether damages were available under the Misrepresentation Act. It would also have decided whether the conspiracy by unlawful means claim was made out on the evidence, including the existence of unlawful means and the necessary participation and intent.
Practically, the outcome would have turned on the court’s findings as to (i) the existence and content of the alleged representations, (ii) their falsity and the defendants’ mental state, (iii) reliance and causation linking the representations to the plaintiffs’ loans and subscription investment, and (iv) whether the conspiracy elements were proven to the required standard. The defendants sought complete dismissal with indemnity costs, indicating that costs and the court’s view of the strength and conduct of the claims were also likely significant.
Why Does This Case Matter?
This case is useful for practitioners because it illustrates how Singapore courts approach multi-layered misrepresentation claims that combine common law fraud/negligence with statutory damages under the Misrepresentation Act. It underscores that claimants must do more than show that a business later underperformed; they must prove actionable misstatements, the representor’s knowledge or negligence, and the causal link to the claimant’s decision-making. For investors and corporate founders alike, the decision highlights the legal risk of presenting a “misleading picture” of viability, particularly where regulatory approvals and product readiness are at different stages.
From an evidence perspective, the judgment’s engagement with hearsay and admissibility demonstrates that misrepresentation and conspiracy cases often depend on documentary and communication evidence, and that the court will scrutinise what can be proved and how. For litigators, this reinforces the importance of building a coherent evidential narrative: identifying the exact statements, proving who made them, and demonstrating how they were relied upon at the time of investment.
Finally, the conspiracy-by-unlawful-means aspect is a reminder that conspiracy is not a “catch-all” for wrongdoing. Claimants must show an agreement and unlawful means, and courts will be cautious where the alleged unlawful means are essentially the same misrepresentations that underpin the misrepresentation claims. The decision therefore provides guidance on how courts may treat overlapping causes of action and how they may require distinct proof for conspiracy.
Legislation Referenced
- Misrepresentation Act (Cap 390, 1994 Rev Ed), s 2(1)
Cases Cited
- [2018] SGHC 123
- [2021] SGHC 246
- [2021] SGHC 84
Source Documents
This article analyses [2021] SGHC 246 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.